Efficacy and safety of choline alphoscerate (cereton) in patients with parkinson’s disease with cognitive impairments

Author： Levin O.   Batukaeva L.   Anikina M.   Yunishchenko N.  

Publisher： Springer Publishing Company

ISSN： 0097-0549

Source： Neuroscience and Behavioral Physiology, Vol.41, Iss.1, 2011-01, pp. : 47-51

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cognitive impairments in Parkinson's disease

By Liu J.H.   Li X.S.   Ye J.   Gao L.H.   Zhang Z.P.   Wu W.   Yao L.   Zhang J.  

Aging and Mental Health, Vol. 16, Iss. 4, 2012-05 ,pp. : 529-536

Routledge Ltd

Access to resources Recommend Favorite

Cognitive impairment in Parkinson’s disease

By Mindham R.H.S.   Hughes T.A.  

International Review of Psychiatry, Vol. 12, Iss. 4, 2000-11 ,pp. : 281-289

Informa Healthcare

Access to resources Recommend Favorite

Impulse control disorders and cognitive dysfunctions in patients with Parkinson’s disease

By Santangelo Gabriella   Trojano Luigi   Barone Paolo   Grossi Dario   Vitale Carmine  

Neurological Sciences, Vol. 34, Iss. 11, 2013-11 ,pp. : 2045-2046

Springer Publishing Company

Access to resources Recommend Favorite

Effects of Amantadine Sulfate on Cognitive Impairments in Patients with Parkinson's Disease

By Yablonskaya A.   Fedorova N.   Belgusheva M.  

Neuroscience and Behavioral Physiology, Vol. 41, Iss. 6, 2011-07 ,pp. : 567-573

Springer Publishing Company

Access to resources Recommend Favorite

Apathy in patients with Parkinson’s disease

By Shulman Lisa M.  

International Review of Psychiatry, Vol. 12, Iss. 4, 2000-11 ,pp. : 298-306

Informa Healthcare

Access to resources Recommend Favorite